NITROL (nitroglycerin) by Pfizer is (no) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic gmp) in smooth muscle and other tissues. First approved in 1983.
Drug data last refreshed 9h ago
NITROL (nitroglycerin) is an injectable vasodilator approved in 1983 that works by activating nitric oxide-dependent guanylate cyclase, increasing cyclic GMP and causing smooth muscle relaxation and vasodilation. It is indicated for acute management of coronary artery disease, heart failure, hypertension, and related cardiovascular conditions. The drug is particularly valuable in acute care settings for rapid hemodynamic stabilization.
As LOE approaches, the brand team will shift focus to generic defense, therapeutic positioning, and managed care negotiations to maintain market presence.
(NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Safety of Nitroglycerin for Field Treatment of STEMI
Treatment of Suspected Cholelithiasis With Nitroglycerin
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Worked on NITROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NITROL offers deep cardiovascular therapeutic expertise and hospital-based market access experience, but limited growth prospects given LOE status. Professionals should expect roles focused on defending market share, managing competitive erosion, and optimizing hospital and specialty pharmacy placement rather than launching new indications.
1 open roles linked to this drug